InMed Pharmaceuticals

What is neuritogenesis and how does it affect Alzheimer's disease progression? Neuritogenesis is the extension of neurites, which are the branchlike structures extending from a neuron and are essential for cell-to-cell communication in the brain. The neuritogenesis process slows down in adults, and to a greater degree in a brain affected by Alzheimer’s disease. The regrowth of neurites or extension of neurites presents an opportunity to reverse neuronal damage caused by Alzheimer’s disease. More here: https://ow.ly/ePkc50V9FFQ $INM #Alzheimers #pathology #neuritogenesis

Population diversity in #Alzheimers clinical trials helps to develop a more personalized treatment plan for patients. Data from a diverse group also gives researchers a deeper understanding of how biomarkers, genetic makeup, geographic impact and other measures impact Alzheimer's disease. More on Alzheimer's clinical trials: https://ow.ly/QOyi50V794y $INM

Researchers at the Allen Institute have uncovered some of the early changes in the brain that occur before Alzheimer's disease symptoms appear. This includes the death of cells called somatostatin (SST) inhibitory neurons. More here: https://ow.ly/7Qgm50V73Ur $INM #Alzheimers #research

In this webinar, Alzheimer's disease experts say advances in diagnostics have been instrumental in understanding Alzheimer's pathology and early disease development. "This disease starts in the brain, with pathology 10 to 20 years before symptoms, so we’ve had a pretty late view of this disease until recently. With some fantastic technology and improvement in the diagnostics, we don’t have to be so late anymore." ~Dr. Phyllis Ferrell, Executive Director of Alzheimer's Moonshot Watch webinar: https://ow.ly/EXvb50V6e7t $INM #Alzheimers #research

Researchers are finding that brain changes can occur 20+ years before #Alzheimer’s disease development. Abnormal levels of neurofilament light chain protein, a biomarker of #neurodegeneration, are found to start about 22 years before #Alzheimers symptoms develop. More in this Alzheimer's Association® report: https://ow.ly/QYY250V5xOO $INM

In a preclinical study, InMed's INM-089 improved the thickness of the outer nuclear layer of the retina where photoreceptors are located. Based on widely accepted research, the thickness of the outer nuclear layer is strongly correlated with photoreceptor preservation and visual acuity. More on INM-089: https://ow.ly/QGHu50V30gI $INM #AMD #dryAMD #macular #degeneration

#ICYMI Article in Fierce Biotech: The Evolving #Alzheimer’s Disease Landscape There have been major advances in #Alzheimers disease research and development in the past two years alone. What are those breakthroughs and what’s in development that may change the course of this disease? “This is an unprecedented time for Alzheimer’s research. Significant advances have been made in understanding pathological factors affecting disease, long-awaited disease-modifying treatments have been approved and more convenient diagnostic tools are becoming available – all major steps in changing the course and impact of this once-elusive disease.” Read article: https://ow.ly/I7Ji50V2s5I $INM

InMed has a robust R&D pipeline with 3 drug candidates: - #Alzheimer’s – multi-factorial approach, reduces #neuroinflammation - #Ocular – functional and pathological improvements for dry #AMD - #Dermatology - Phase 2 completed in #epidermolysis #bullosa More: https://ow.ly/3T9V50V2cfj $INM #pharma

In this webinar, #Alzheimer's disease experts talk about the causal link between #inflammation and #Alzheimers disease development and progression. "We were looking at the genes that modify the risk, and many of these genes are found in the innate immune system and only in the innate immune system cells, so this is telling us that there’s some causal linkage between inflammation and the disease itself." ~Dr. David Morgan, Michigan State University Watch webinar: https://ow.ly/jb7J50UYPir $INM #neuroinflammation

#Alzheimers Disease Research There are 164 clinical trials assessing 127 drug candidates for #Alzheimer's disease, targeting a wide spectrum of processes including #inflammation, #amyloid and #neurotransmitter receptors. 96 of those drug candidates are disease-modifying agents. More in 2024 journal article: https://ow.ly/h9L150UY65B $INM